Oryzon Genomics SA (ES:ORY) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Oryzon Genomics has announced a capital increase through the issuance of 500,789 new shares following a convertible bond conversion requested by Nice & Green SA, totaling approximately 919,999 euros in effective capital. The new shares, priced at 1.8371 euros each, will expand the company’s share capital to 3,200,592.90 euros. These shares will be admitted to trading on the main Spanish stock exchanges.
For further insights into ES:ORY stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue